Dr. Stephan Miller and colleagues at the University of Tübingen in Germany have discovered that silent myocardial infarction raises the likelihood of a future major cardiac event for 14% of patients with symptomatic peripheral vascular disease evaluated with MRA.
Dr. Stephan Miller and colleagues at the University of Tübingen in Germany have discovered that silent myocardial infarction raises the likelihood of a future major cardiac event for 14% of patients with symptomatic peripheral vascular disease evaluated with MRA.
They made the finding after developing a new MR protocol that combined delayedenhancement myocardial MRA with a conventional contrast-enhanced peripheral vascular runoff study. The delayed myocardial perfusion images were acquired 10 minutes after MRA using the same 0.18-mmol administration of gadolinium-based contrast media.
Evidence of a previous myocardial infarction appeared for 58 of 182 (32%) patients with confirmed peripheral vascular disease. Twenty-six patients, in consultations after the procedure, admitted that they were not aware of their previous infarction. The clinical relevance of the findings proved themselves out when subjects were interviewed two years later. Major adverse cardiac events, such as unstable angina, revascularization, or cardiac-related death, arose among eight of 26 (31%) patients with an occult progressing infarction. The MACE rate for patients with unknown infarction was 34% and 6% for patients whose delayed-enhancement MRA studies ruled out MI.
Miller concluded that the add-on cardiac sequence is a meaningful supplement to peripheral vascular MRI that provides important information to help physicians stratify patient risk and choose optimal therapy.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.